证券研究报告：医药生物 | 公司点评报告 发布时间：2026-03-20 股票投资评级 买入 |首次覆盖 个股表现 2025-03 2025-05 2025-08 2025-10 2025-12 2026-03 -27% -21% -15% -9% -3% 3% 9% 15% 21% 27% 33% 药康生物 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 15.06 | | --- | --- | | 总股本/流通股本（亿股）4.10 | / 4.10 | | 总市值/流通市值（亿元）62 | / 62 | | 52 周内最高/最低价 | 19.75 / 10.92 | | 资产负债率(%) | 17.0% | | 市盈率 | 55.78 | | 第一大股东 | 南京老岩创业投资合伙 | | | 企业(有限合伙) | 药康生物(688046) 主业增速稳健，国际化与创新战略成果持续兑现 l 投资要点 事件：公司发布 2025 年业绩快报，全年实现营业收入 7.93 亿元 （+15.49%），归母净利润 1.44 亿元（+31.49%），扣非净利润 1.18 亿元（+55.8 ...

2025-03 2025-05 2025-08 2025-10 2025-12 2026-03 -27% -21% -15% -9% -3% 3% 9% 15% 21% 27% 33% 药康生物 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 15.06 | | --- | --- | | 总股本/流通股本（亿股）4.10 | / 4.10 | | 总市值/流通市值（亿元）62 | / 62 | | 52 周内最高/最低价 | 19.75 / 10.92 | | 资产负债率(%) | 17.0% | | 市盈率 | 55.78 | | 第一大股东 | 南京老岩创业投资合伙 | | | 企业(有限合伙) | 证券研究报告：医药生物 | 公司点评报告 发布时间：2026-03-20 股票投资评级 买入 |首次覆盖 个股表现 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 药康生物(68 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with annual growth rates of 20.5%, 10.4%, 15.5%, 17.7%, and 17.6% respectively [4][11]. - Net profit attributable to the parent company is expected to fluctuate, with estimates of 159 million CNY in 2023, dropping to 110 million CNY in 2024, and then recovering to 205 million CNY by 2027 [4][11]. - Earnings per share (EPS) is projected to increase from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][11]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive significant revenue growth [17][27]. - The commercialized mouse model segment is the cornerstone of the business, with revenue growth supported by an increase in high-end product sales and operational efficiency improvements [22][27]. - The pharmacodynamic service segment is expected to become a key revenue growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company has seen significant growth in overseas revenue, reaching 1.07 billion CNY in the first three quarters of 2025, a year-on-year increase of 23.62% [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive further revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to future growth [33][34]. Profitability Forecast and Investment Recommendations - The company is projected to achieve revenues of 9.34 billion CNY and 10.99 billion CNY in 2026 and 2027, respectively, with corresponding net profits of 1.74 billion CNY and 2.05 billion CNY [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services, along with ongoing overseas expansion, will enhance profitability [10][42]. - A valuation based on comparable companies suggests a target price of 23.65 CNY, reflecting a 55 times PE ratio for 2026 [10][40][42].

Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 23.65 CNY, compared to the current price of 15.11 CNY [5][10][42]. Core Insights - The demand for innovative drug development is recovering, coupled with growth in overseas business, driving profitability recovery for the company, indicating a new growth cycle [2][10]. - The company is expected to achieve revenue of 7.93 billion CNY in 2025, representing a year-on-year growth of 15.5%, with a net profit of 1.44 billion CNY, reflecting a growth of 31.5% [10][15][42]. - The core business structure is optimized, with high-end models and pharmacodynamic services driving growth, accounting for over 90% of total revenue [17][22]. Financial Summary - Total revenue is projected to grow from 622 million CNY in 2023 to 1.099 billion CNY in 2027, with a compound annual growth rate (CAGR) of 17.6% [4][39]. - Net profit attributable to the parent company is expected to increase from 159 million CNY in 2023 to 205 million CNY in 2027, with a significant growth of 31.5% in 2025 [4][42]. - Earnings per share (EPS) is forecasted to rise from 0.39 CNY in 2023 to 0.50 CNY in 2027 [4][42]. Business Analysis - The core business includes commercialized mouse models, pharmacodynamic services, and custom breeding, which collectively drive revenue growth [17][27]. - The commercialized mouse model business is the cornerstone, with revenue growth supported by an increase in high-end product sales and improved gross margins [22][25]. - The pharmacodynamic service segment is expected to become a significant growth engine, benefiting from increased demand for drug testing and model services [25][38]. Overseas Business Growth - The company reported overseas revenue of 1.07 billion CNY in the first three quarters of 2025, marking a year-on-year increase of 23.62%, with a notable 63.97% growth in Q3 [29][32]. - The establishment of a new headquarters in San Diego enhances local service capabilities, which is expected to drive future revenue growth [29][32]. - The company is also developing a humanized antibody discovery platform, which is anticipated to contribute to long-term growth potential [33][34]. Profitability Forecast and Investment Recommendations - Revenue is projected to grow steadily, with expectations of 9.34 billion CNY in 2026 and 10.99 billion CNY in 2027, maintaining a growth rate of 17.7% and 17.6% respectively [42]. - The report suggests that the company’s strong technical advantages in commercialized mouse models and pharmacodynamic services will enhance profitability over time [10][42]. - Based on comparable company valuations, a price-to-earnings (PE) ratio of 55 times for 2026 is recommended, leading to a target price of 23.65 CNY [10][40][42].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][8]. Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11]. - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [1][21]. - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [1][26]. Summary by Sections Government Positioning - The government has upgraded the status of the biotechnology and pharmaceutical industry, highlighting its role in driving new productivity and technological innovation [2][11]. - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic healthcare services [13]. Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78% [1][21]. - Specific sub-sectors such as medical services and medical devices experienced significant declines, with medical services down 4.71% [1][21]. Valuation Metrics - The TTM price-to-earnings ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26]. Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (300760.SZ): Strong in R&D and international expansion [30]. - United Imaging Healthcare (688271.SH): Focused on high-performance medical imaging and digital solutions [30]. - WuXi AppTec (603259.SH): A leading open-access drug development service platform [30]. - Aier Eye Hospital (300015.SZ): The largest eye care institution in China [30]. - Yuyue Medical (002223.SZ): A leading provider of medical devices and solutions [31].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11] - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [21] - The current price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [26] Summary by Sections Government Work Report - The report highlights the establishment of biotechnology and pharmaceuticals as a new pillar industry, with a focus on innovation and the development of new technologies such as artificial intelligence and quantum technology [2][11] - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic medical services [13] Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78%, indicating weaker performance compared to the broader market [21] - Specific declines were noted in various sub-sectors, including medical services down 4.71% and medical devices down 2.94% [21] Valuation Metrics - The P/E ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26] Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (迈瑞医疗): A leader in medical devices with strong R&D and international expansion [30] - United Imaging Healthcare (联影医疗): Focused on high-performance medical imaging and digital solutions [30] - WuXi AppTec (药明康德): A comprehensive drug development service platform benefiting from global outsourcing trends [30] - Aier Eye Hospital (爱尔眼科): The largest eye care institution in China, leveraging international technology and management [30]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

公司状况 公司此前公告的回购计划(期限为2024年10月31日起12个月内)可能已接近尾声或完成，但无最新进展更 新。公司作为国家级专精特新"小巨人"企业，持续探索AI技术在研发中的应用，这些是长期关注点。 以上内容基于公开资料整理，不构成投资建议。 经济观察网药康生物(688046.SH)近期披露2025年度业绩快报，显示营业收入同比增长15.49%至7.93亿 元，归母净利润同比增长31.49%至1.44亿元。公司2025年年度报告即将正式发布，将提供更详细的财务 和经营数据。 业绩经营情况 公司已于2026年2月3日披露2025年度业绩快报，显示营业收入同比增长15.49%至7.93亿元，归母净利润 同比增长31.49%至1.44亿元。根据证券之星的报道，2025年年度报告即将正式发布，这将提供更详细的 财务和经营数据。 ...

Company and Industry Summary Company: 药康生物 (Yaokang Biotechnology) Key Financial Performance - FY 2025 revenue reached 793 million yuan, representing a year-over-year increase of 15.5% [1] - Net profit attributable to shareholders was 144 million yuan, up 31.5% [1] - Non-recurring net profit stood at 118 million yuan, reflecting a significant increase of 55.8% [1] - Q4 2025 revenue was 218 million yuan, showing a growth of 22.9% [1] - Net profit for Q4 was 35 million yuan, a remarkable increase of 197% [1] - Non-recurring net profit for Q4 was 25 million yuan [1] Growth Drivers - Sales of mouse models experienced double-digit growth [1] - Functional efficacy CRO (Contract Research Organization) services grew at a rate of 30-40% [1] Industry Trends - The domestic industry is seeing an improvement in demand, with a recovery in the industrial sector [1] - Anticipated continued positive trends in the domestic market for Q1 2026 [1] - Overseas growth is projected at 40-50%, with an expanding network across Europe, America, and Asia [1] - High growth in overseas markets is expected to persist into 2026 [1] Long-term Outlook - Short-term optimism for the clinical pre-CRO sector in 2026 [1] - Long-term confidence in the business model of globally leading gene-edited mice, driven by China's engineering talent advantage [1] Industry Recommendations - Recommended stocks include 百奥赛图 (Baiaosaitu), 药康生物 (Yaokang Biotechnology), and 南模生物 (Nanmo Biotechnology) [2]

Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 793.25 million RMB, an increase of 15.49% compared to the previous year [1] - The net profit attributable to the parent company was 144.40 million RMB, reflecting a 31.49% increase year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 118.01 million RMB, showing a significant increase of 55.80% [1] - Total assets at the end of the reporting period were 2,872.76 million RMB, up 11.67% from the beginning of the period [1] - Equity attributable to the parent company increased by 4.44% to 2,229.50 million RMB [1] Operational Performance Factors - The company focused on internationalization and innovation as core strategies, expanding overseas markets and maintaining high R&D investment to stay at the forefront of technology and products [2] - Revenue growth was driven by an expanding sales network covering North America, Europe, and Asia-Pacific, leading to increased customer numbers and brand recognition [2] - Domestic revenue growth was supported by improved industry conditions and increased R&D investments from downstream industrial clients, resulting in a notable recovery in demand [2]